{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:23:21Z","timestamp":1788200601085,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T00:00:00Z","timestamp":1540425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.ejphar.2018.10.021","type":"journal-article","created":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T01:25:35Z","timestamp":1539998735000},"page":"139-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Pharmacology of Parsabiv\u00ae (etelcalcetide, ONO-5163\/AMG 416), a novel allosteric modulator of the calcium-sensing receptor, for secondary hyperparathyroidism in hemodialysis patients"],"prefix":"10.1016","volume":"842","author":[{"given":"Kazutsune","family":"Harada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiko","family":"Fujioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Konno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuto","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Hirota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2018.10.021_bib1","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1124\/mol.115.098392","article-title":"Critical cysteine residues in both the calcium-sensing receptor and the allosteric activator AMG 416 underlie the mechanism of action","volume":"88","author":"Alexander","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.10.021_bib2","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/ki.2014.349","article-title":"Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism","volume":"87","author":"Behets","year":"2015","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2018.10.021_bib3","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2018.10.021_bib4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1517\/17460441003615170","article-title":"Parathyroid gland regulation: contribution of the in vivo and in vitro models","volume":"5","author":"Carrillo-L\u00f3pez","year":"2010","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ejphar.2018.10.021_bib5","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options","volume":"6","author":"Cunningham","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2018.10.021_bib6","series-title":"Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis","author":"Corpeland","year":"2000"},{"key":"10.1016\/j.ejphar.2018.10.021_bib7","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/ndt\/gfw408","volume":"32","author":"Fukagawa","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ejphar.2018.10.021_bib8","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1254\/fpj.150.98","article-title":"The pharmacological profile and the clinical efficacy of the world's 1st intravenous calcimimetics; etelcalcetide hydrochloride (Parsabiv\u00ae)","volume":"150","author":"Harada","year":"2017","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"10.1016\/j.ejphar.2018.10.021_bib9","first-page":"537","article-title":"The discovery, research and development of etelcalcetide hydrochloride, the world 1st intravenous calcimimetics","volume":"27","author":"Inoue","year":"2017","journal-title":"Clin. Calcium"},{"key":"10.1016\/j.ejphar.2018.10.021_bib10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.18553\/jmcp.2007.13.5.397","article-title":"Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment","volume":"13","author":"Joy","year":"2007","journal-title":"J. Manag. Care Pharm."},{"key":"10.1016\/j.ejphar.2018.10.021_bib11","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/ki.2008.407","article-title":"Cinacalcet suppresses calcification of the aorta and heart in uremic rats","volume":"74","author":"Kawata","year":"2008","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2018.10.021_bib12","series-title":"Regpara [Drug Interview Form]","author":"Kyowa Hakko Kirin Co., Ltd.","year":"2017"},{"key":"10.1016\/j.ejphar.2018.10.021_bib13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.bone.2017.08.026","article-title":"Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism","volume":"105","author":"Li","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.ejphar.2018.10.021_bib14","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/ki.2013.289","article-title":"AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients","volume":"85","author":"Martin","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2018.10.021_bib15","first-page":"1567","article-title":"Cinacalcet hydrochloride and phosphate metabolism","volume":"22","author":"Nagano","year":"2012","journal-title":"Clin. Calcium"},{"key":"10.1016\/j.ejphar.2018.10.021_bib16","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0022-3565(24)29333-2","article-title":"Calcilytic compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone","volume":"299","author":"Nemeth","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2018.10.021_bib17","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1124\/jpet.103.057273","article-title":"Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl","volume":"308","author":"Nemeth","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2018.10.021_bib18","unstructured":"Ono Pharmaceutical Co., Ltd., 2016. Etelcalcetide application dossier CTD 2.6.2.6. \u3008http:\/\/www.pmda.go.jp\/drugs\/2016\/P20161220003\/index.html\u3009, (Accessed 6 August 2018). [in Japanese]."},{"key":"10.1016\/j.ejphar.2018.10.021_bib19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1113\/jphysiol.1993.sp019765","article-title":"Protein kinase C modulates hormone secretion regulated by extracellular polycations in bovine parathyroid cells","volume":"468","author":"Racke","year":"1993","journal-title":"J. Physiol."},{"key":"10.1016\/j.ejphar.2018.10.021_bib20","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","article-title":"The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis","volume":"26","author":"Raggi","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ejphar.2018.10.021_bib21","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1073\/pnas.84.10.3269","article-title":"Functional epithelial cell line cloned from rat parathyroid glands","volume":"84","author":"Sakaguchi","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejphar.2018.10.021_bib22","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s10157-017-1442-5","article-title":"Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism","volume":"22","author":"Shigematsu","year":"2018","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.ejphar.2018.10.021_bib23","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1046\/j.1523-1755.1998.00782.x","article-title":"NPS R-568 halts or reverses osteitis fibrosa in uremic rats","volume":"53","author":"Wada","year":"1998","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2018.10.021_bib24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1471-2369-15-81","article-title":"Comparison of AMG 416 and cinacalcet in rodent models of uremia","volume":"15","author":"Walter","year":"2014","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.ejphar.2018.10.021_bib25","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/jpet.113.204834","article-title":"Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients","volume":"346","author":"Walter","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2018.10.021_bib26","doi-asserted-by":"crossref","first-page":"68","DOI":"10.5414\/CN108974","article-title":"A 12-week dose-escalating study of etelcalcetide (ONO-5163\/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese hemodialysis patients","volume":"88","author":"Yokoyama","year":"2017","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.ejphar.2018.10.021_bib27","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.ekir.2017.01.016","article-title":"A single- and multiple-dose, multicenter study of etelcalcetide in Japanese hemodialysis patients with secondary hyperparathyroidism","volume":"2","author":"Yokoyama","year":"2017","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.ejphar.2018.10.021_bib28","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00223-017-0319-7","article-title":"Etelcalcetide, a novel calcimimetic, prevents vascular calcification in a rat model of renal insufficiency with secondary hyperparathyroidism","volume":"101","author":"Yu","year":"2017","journal-title":"Calcif. Tissue Int."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918306083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918306083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T20:54:49Z","timestamp":1775249689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299918306083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":28,"alternative-id":["S0014299918306083"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.10.021","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacology of Parsabiv\u00ae (etelcalcetide, ONO-5163\/AMG 416), a novel allosteric modulator of the calcium-sensing receptor, for secondary hyperparathyroidism in hemodialysis patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.10.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}